Radiopharm Theranostics Limited RADX
0.84 USD -0.04 (-4.75%)
At closeNov 10, 2026, 4:00 PM EST
0.85 +0.01 +0.83%
After hours · Nov 10, 4:00 PM ET
0.843 Day range 0.9419
0.81 52-week range 16.25
- YTD
- -83.85%
- 1 year
- -83.00%
News
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Curis (NASDAQ:CRIS) stock moved upwards by 83.5% to $1.31 during Wednesday's pre-market session. The company's market cap stands at $1.7 million. SCWorx (NASDAQ:WORX) stock increased by…
globenewswire.com Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain Metastases Single, multicenter Phase 3 imaging trial of approximately 280 patients with brain metastases designed to demonstrate sensitivity and specificity above prespecified performance thresholds
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares…
benzinga.com Radiopharm Theranostics Announces Completion Of EOP2 Meeting With FDA Regarding RAD101, Investigational Radiopharmaceutical Imaging Agent For Detection Of Brain Metastases Constructive FDA interaction provides clear framework for RAD101 pivotal clinical development plan in brain metastases imagingCurrently executing Phase 3 readiness activities in anticipation of FDA…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Circle8 Group (NASDAQ:CIRC) stock moved upwards by 14.6% to $0.57 during Monday's after-market session. The company's market cap stands at $50.2 million. Eocene (NASDAQ:EOCN) shares rose…
benzinga.com Radiopharm Says Data From Interim Analysis Of Phase 2b Imaging Clinical Trial Of 18F-RAD101 In Participants With Suspected Recurrent Brain Metastases From Solid Tumors Selected For Presentation At SNO26 Annual Meeting RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpointMeeting with FDA planned on October 1st to align on RAD101Phase 3 pivotal trial…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 49.2% to $7.91 during Friday's pre-market session. The company's market cap stands at $3.5 million. Biodexa Pharmaceuticals (NASDAQ:BDRX)…- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 48.8% to $3.63 during Thursday's pre-market session. The market value of their outstanding shares is at $1.6 million. AEON Biopharma…
- benzinga.com Radiopharm Theranostics Shares Data From Phase 1 Imaging Trial of RAD 301 In Healthy Volunteers And Subjects With Pancreatic Ductal Adenocarcinoma RAD301 is a peptide-based molecule bound to Gallium-68 (Ga-68) that targets αvβ6-integrin, a cellular marker for tumor invasion and metastatic growth, the expression of which correlates with…
benzinga.com Radiopharm Doses First Patient In Second Cohort Of Its First-In-Human Phase 1/2a Clinical Trial Of RV-01 In Patients With B7-H3 Expressing Tumors Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of…- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Picard Medical (AMEX:PMI) shares moved upwards by 34.6% to $4.32 during Monday's pre-market session. The company's market cap stands at $6.5 million. As per the press release, Q2 earnings…
- benzinga.com Radiopharm Theranostics Schedules An FDA End-Of-Phase 2 For October 1, 2026, To Align On The Design Of A Pivotal Phase 3 Trial To Evaluate RAD101 In Patients With Suspected Recurrence Of Brain Metastases Following Radiotherapy RAD101 is the Company's novel Fluorine-18-labeled small-molecule imaging agent that targets fatty acid synthase (FASN) and is being developed to diagnose suspected recurrent brain metastases arising…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 62.5% to $4.47 during Wednesday's pre-market session. The company's market cap stands at $1.4 million. OneMedNet (NASDAQ:ONMD) shares…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market session. The company's market cap stands at $66.4 million. ProMIS Neurosciences (NASDAQ:PMN) shares…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Tenet Healthcare (NYSE:THC) stock increased by 17.3% to $233.54 during Friday's regular session. The market value of their outstanding shares is at $17.4 billion. The company's, Q2 earnings…
benzinga.com US Stocks Mixed; American Express Shares Fall Following Q2 Results US stocks mixed, Dow Jones up 0.2%. Real estate shares up 1.3%. American Express falls 6%. Ohmyhome, LiveWire, Vivakor surge. Robin Energy, RADIOPHARM, Codexis down.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 28.3% to $21.53 during Friday's pre-market session. The company's market cap stands at $27.4 million. Akanda (NASDAQ:AKAN) shares…
benzinga.com Radiopharm Theranostics Announces $4.1M U.S. Direct Offering Of Shares And Warrants Along With A$12.7M ($8.9M) Australian Placement Radiopharm Theranostics Limited (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for…
benzinga.com Radiopharm Theranostics Announces Updated Clinical Results From First Two Patients In Third Cohort Of RAD204; First RECIST-Confirmed Durable Partial Response At Current Highest Dose Level #3, With Patient Progression Free Beyond Seven Months Second patient dosed remains progression free on treatment with RAD204 with early tumor shrinkage observed after first treatmentRAD204 is generally well-tolerated with no dose-limiting toxicities…- benzinga.com Radiopharm Theranostics Announces Data From All Thirty Evaluable Patients In Its Phase 2B Trial Of RAD101 In Participants With Suspected Recurrence Of Brain Metastases After Radiotherapy; RAD101 PET Demonstrated 93% Concordance With MRI Across All Evaluable Lesions, Meeting The Primary Endpoint 14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) Sensitivity (secondary objective). Specificity data will be available in Q4 2026.The Company plans to…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.9 million. Imunon (NASDAQ:IMNN) shares…
benzinga.com This HC Wainwright & Co. Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday Wall Street analysts began coverage on top names, including a bullish rating on Radiopharm Theranostics. See more analyst ratings.
benzinga.com HC Wainwright & Co. Initiates Coverage On Radiopharm Theranostics with Buy Rating, Announces Price Target of $16 HC Wainwright & Co. analyst Robert Burns initiates coverage on Radiopharm Theranostics (NASDAQ:RADX) with a Buy rating and announces Price Target of $16.
benzinga.com Radiopharm Theranostics Issues Business Update Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of…- benzinga.com Radiopharm Theranostics Announces That New Data From The Ongoing Phase 0/1 Heat Trial Evaluating 177Lu-RAD202, A First-In-Class HER2-targeted Radiopharmaceutical Therapy, Will Be Presented As A Poster At The American Association For Cancer Research Annual Meeting on April 17–22 Key Findings from the AACR Abstract and PosterMeaningful tumor uptake of 177Lu-RAD202 was observed at the initial and lowest dose level of 30 mCi, particularly in breast cancer lesions177Lu-RAD202…
- benzinga.com Radiopharm Announces Dosing Of Final Patient In Phase 2b Imaging Trial Evaluating RAD 101 In Individuals With Confirmed Recurrent Brain Metastases From Solid Tumors Of Different Origins The U.S. multicenter, open-label, single arm Phase 2b clinical trial is evaluating the diagnostic performance of 18F-RAD101 in 30 individuals with confirmed recurrent brain metastases from solid…
- benzinga.com Radiopharm Theranostics Advances Cancer Drug Trial After Safety Review Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of…
- benzinga.com Radiopharm Theranostics Says First Patient Dosed In First-In-Human Phase 1 Clinical Trial Of RAD 402, Monoclonal Antibody Targeting KLK3 Radiolabelled With Terbium 161 Being Evaluated In Advanced Prostate Cancer On track to share data from first two dose levels in 2H 2026Targeting KLK3 and leveraging the dual emission of Tb161 represents an innovative approach for radiotherapies in Prostate CancerPreclinical…
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Radiopharm Theranostics Eyes Pivotal Trial Path After Encouraging Interim Results Radiopharm Theranostics says Phase 2b interim data showing 90% MRI concordance for RAD 101, with final readout expected by June.- benzinga.com Radiopharm Drug Shows 90% Accuracy In Detecting Brain Tumors In Trial Radiopharm Theranostics (ASX: RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet…
benzinga.com Radiopharm Theranostics Doses First Participant In Phase 1/2 Clinical Study Of 177Lu-Betabart Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet…- benzinga.com Radiopharm Theranostics Says Cash And Cash Equivalents Of Approximately $34.52m For Or The 6 Months Ended December 31, 2025 Provide Runway Into 2027 Program and Business Updates18F-RAD101 – Small molecule targeting fatty acid synthase radiolabeled with Fluorine-18RAD 101 is being evaluated in a single-arm U.S. Phase 2b clinical trial for the…
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Radiopharm Theranostics Raises Radiopharm Ventures Stake From 75% To 87.5% With Lead B7H3 Candidate Betabart Advancing Toward First Patient Dosing In Q1 2026 Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and Radiopharm TheranosticsLeading candidate Betabart, a monoclonal antibody targeting B7H3, has…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Benzinga Bulls And Bears: Carnival, Caterpillar, Meta — And Markets Make Modest Gains Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com B. Riley Securities Reiterates Buy on Radiopharm Theranostics, Raises Price Target to $16 B. Riley Securities analyst Yuan Zhi reiterates Radiopharm Theranostics (NASDAQ:RADX) with a Buy and raises the price target from $13 to $16.
benzinga.com Dow Falls 50 Points; US Adds 64,000 Jobs In November - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Why Is Radiopharm Theranostics Stock Rallying Over 140%? Radiopharm Theranostics shares rise after interim Phase 2b data showed 92% MRI concordance for RAD 101 imaging in brain metastases.- benzinga.com Market-Moving News for December 15th RADX: 471% | Radiopharm Theranostics' Interim Data From The First Twelve Patients In Its U.S. Phase 2b Imaging Trial Of RAD 101 In Brain Metastases Showed That 92% Of The Patients Achieved…